{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ixempra+%28Ixabepilone+%28BMS-247550%29+%29&page=2", "query": { "intervention": "Ixempra (Ixabepilone (BMS-247550) )", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 105, "total_pages": 11, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ixempra+%28Ixabepilone+%28BMS-247550%29+%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Ixempra+%28Ixabepilone+%28BMS-247550%29+%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-11T16:20:39.659Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00821886", "title": "Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Ixabepilone", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2009-02", "completion_date": "2014-10", "has_results": true, "last_update_posted_date": "2014-12-22", "last_synced_at": "2026-10-11T16:20:39.659Z", "location_count": 12, "location_summary": "Fort Myers, Florida • Augusta, Georgia • Terre Haute, Indiana + 8 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Terre Haute", "state": "Indiana" }, { "city": "Portland", "state": "Maine" }, { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00821886" }, { "nct_id": "NCT00036764", "title": "BMS-247550 in Treating Patients With Stage IV Melanoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Melanoma", "Stage IV Melanoma" ], "interventions": [ { "name": "ixabepilone", "type": "DRUG" }, { "name": "pharmacogenomic studies", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 88, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-01-25", "last_synced_at": "2026-10-11T16:20:39.659Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036764" }, { "nct_id": "NCT00825734", "title": "Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "Sorafenib", "type": "DRUG" }, { "name": "Ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SCRI Development Innovations, LLC", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2009-03", "completion_date": "2014-08", "has_results": true, "last_update_posted_date": "2014-12-22", "last_synced_at": "2026-10-11T16:20:39.659Z", "location_count": 15, "location_summary": "Fort Myers, Florida • Terre Haute, Indiana • Louisville, Kentucky + 10 more", "locations": [ { "city": "Fort Myers", "state": "Florida" }, { "city": "Terre Haute", "state": "Indiana" }, { "city": "Terre Haute", "state": "Indiana" }, { "city": "Louisville", "state": "Kentucky" }, { "city": "Baton Rouge", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT00825734" }, { "nct_id": "NCT00331344", "title": "Treating Patients With Metastatic Prostate Cancer Not Responding to Hormone and Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adenocarcinoma of the Prostate", "Recurrent Prostate Cancer", "Stage IV Prostate Cancer" ], "interventions": [ { "name": "mitoxantrone hydrochloride", "type": "DRUG" }, { "name": "ixabepilone", "type": "DRUG" }, { "name": "prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 100, "start_date": "2006-04", "completion_date": "2010-11", "has_results": true, "last_update_posted_date": "2017-10-31", "last_synced_at": "2026-10-11T16:20:39.659Z", "location_count": 2, "location_summary": "San Francisco, California • Madison, Wisconsin", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00331344" }, { "nct_id": "NCT00006221", "title": "BMS-247550 in Treating Patients With Advanced Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2000-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-11", "last_synced_at": "2026-10-11T16:20:39.659Z", "location_count": 3, "location_summary": "San Antonio, Texas", "locations": [ { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006221" }, { "nct_id": "NCT02915744", "title": "A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Metastasis", "Breast Cancer" ], "interventions": [ { "name": "NKTR-102", "type": "DRUG" }, { "name": "Eribulin", "type": "DRUG" }, { "name": "Ixabepilone", "type": "DRUG" }, { "name": "Vinorelbine", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Nektar Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 178, "start_date": "2016-11", "completion_date": "2020-07", "has_results": true, "last_update_posted_date": "2023-04-14", "last_synced_at": "2026-10-11T16:20:39.659Z", "location_count": 19, "location_summary": "Tucson, Arizona • Orange, California • San Francisco, California + 16 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Plantation", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02915744" }, { "nct_id": "NCT00309049", "title": "Ixabepilone Administered as an Enteric Coated Formulation.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "R-Pharm", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2006-04", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-10-11T16:20:39.659Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Detroit, Michigan", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00309049" }, { "nct_id": "NCT01012362", "title": "Study of Pazopanib and Ixabepilone in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Lung Cancer", "Colon Cancer", "Pancreatic Cancer", "Head and Neck Cancer", "Kidney Cancer", "Sarcoma", "Hepatocellular Cancer" ], "interventions": [ { "name": "Pazopanib", "type": "DRUG" }, { "name": "Ixabepilone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 31, "start_date": "2009-12", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2017-12-28", "last_synced_at": "2026-10-11T16:20:39.659Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01012362" }, { "nct_id": "NCT00079326", "title": "Trastuzumab and Ixabepilone in Treating Women With HER2-Positive Metastatic Breast Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2-positive Breast Cancer", "Recurrent Breast Cancer", "Stage IV Breast Cancer" ], "interventions": [ { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "ixabepilone", "type": "DRUG" }, { "name": "laboratory biomarker analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 39, "start_date": "2004-01", "completion_date": "2010-10", "has_results": true, "last_update_posted_date": "2014-06-02", "last_synced_at": "2026-10-11T16:20:39.659Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00079326" }, { "nct_id": "NCT02067416", "title": "PREDATOR: Neoadjuvant Gene Prediction for Breast Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Anthracycline based chemotherapy", "type": "DRUG" }, { "name": "taxane-based chemotherapy", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jenny C. Chang, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2012-07", "completion_date": "2014-06", "has_results": false, "last_update_posted_date": "2023-02-02", "last_synced_at": "2026-10-11T16:20:39.659Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02067416" } ] }